(Q53655424)

16 May 2018

title

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. (English)

1 reference

16 May 2018

main subject

phase II clinical trial

0 references

0 references

David Miller

1 reference

16 May 2018

author name string

Paul O'Connor

1 reference

16 May 2018

Katherine Riester

1 reference

16 May 2018

Minhua Yang

1 reference

16 May 2018

Michael Panzara

1 reference

16 May 2018

Catherine Dalton

1 reference

16 May 2018

Katherine Miszkiel

1 reference

16 May 2018

Omar Khan

1 reference

16 May 2018

George Rice

1 reference

16 May 2018

William Sheremata

1 reference

16 May 2018

International Natalizumab Trial Group

1 reference

16 May 2018

publication date

1 October 2005

1 reference

16 May 2018

Multiple Sclerosis Journal

published in

1 reference

16 May 2018

volume

1 reference

16 May 2018

issue

1 reference

16 May 2018

page(s)

568-572

1 reference

16 May 2018

Integrins: a family of cell surface receptors

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

A reproducible repositioning method for serial magnetic resonance imaging studies of the brain in treatment trials for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1205OA

10.1191/1352458505MS1205OA

21 January 2018

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018